Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study Felip, E., Altorki, N., Zhou, C., Vallieres, E., Vynnychenko, I., Akopov, A., Martinez-Marti, A., Chella, A., Bondarenko, I., Ursol, G., Levchenko, E., Kislov, N., Liersch, R., Belleli, R., Mcnally, V., Bennett, E., Gitlitz, B., Wakelee, H. KARGER. 2022: 146-147

View details for Web of Science ID 000883051700343